Prognostic value of <i>EGFR</i> mutations in surgically resected pathological stage I lung adenocarcinoma
Teppei Nishii(Kanagawa Cancer Center), Munetaka Masuda(Uji Hospital), Tetsuya Isaka(Kanagawa Cancer Center), Tomoyuki Yokose(Kanagawa Prefectural Hospital Organization), Haruhiro Saito(Kanagawa Cancer Center), Hideyuki Furumoto(Kanagawa Prefectural Hospital Organization), Tetsuro Kondo(Kanagawa Prefectural Hospital Organization), Yataro Daigo(The University of Tokyo), Yohei Miyagi(Kanagawa Cancer Center), Fumihiro Oshita(Kanagawa Cancer Center), Shoichi Matsukuma(Kanagawa Cancer Center), Haruhiko Nakayama, Kouzo Yamada(Kanagawa Cancer Center), Hiroyuki Ito(Kanagawa Prefectural Hospital Organization), Shuji Murakami(Kanagawa Cancer Center)
Cited by 25
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
HJURP Is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres
|Cell|2009|636
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Mutations truncating the EP300 acetylase in human cancers
|Nature Genetics|2000|593